跳至主要内容
临床试验/IRCT2015070822991N2
IRCT2015070822991N2已完成未知

Effect of olanzapine on symptom- relief and quality of life in gastric cancer patients receiving chemotherapy

Babol University of Medical Sciences0 个研究点目标入组 30 人开始时间: 待定最近更新:
适应症

试验速览

阶段
未知
状态
已完成
入组人数
30

研究概览

简要总结

暂无简介。

研究设计

研究类型
Interventional

入排标准

年龄范围
no limit 至 no limit(—)
性别
All

入选标准

  • gastric cancer patients whose disease diagnosed recently and candidate for chemotherapy; patient´s informed consent for participation in the study
  • Exclusion criteria: history of severe psychiatric problems such as severe cognitive disorders, psychotic disorders, antipsychotic medication such as risperidone, clozapine, phenothiazine,… in 30 days before or duration of the protocol; history of severe neurologic diseases such as metastasis to the brain, convulsion, ...; mental retardation; serum creatinine level more than 2 milligram per deciliter; total serum bilirubin level more than 2 milligram per deciliter; hepatic enzymes more than three times higher than upper limit of normal range; neutrophil count less than 1500; pregnancy; uncontrolled cardiac diseases such as cardiac arrhythmias, heart failure, acute myocardial infarction in the last 6 months; uncontrolled diabetes mellitus

排除标准

  • 未提供

研究者

相似试验